- Resonance Health (RHT) has received a key clearance for its HepaFat product from the U.S. Food and Drug Administration (FDA)
- The product essentially works as a non-invasive medical device which measures the volume fraction of fat in liver tissue
- This approval from the FDA will also allow Resonance to market HepaFat for commercial distribution in the U.S.
- The company’s CEO has labeled the 501(k) clearance an “outstanding result”
- Company CEO Alison Laws also said the clearance is an important milestone for Resonance
- Shareholders agree, with Resonance shares shooting up 41.9 percent and trading at 22 cents each
